Table monthly_update_prescription_drug_wac

Table: monthly_update_prescription_drug_wac_inc , manufacturer_name like P*

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	gross_sales_us_dollars	gross_sales_us_dollars_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000484	Pacira Pharmaceuticals, Inc.	04/24/2025	65250013309	EXPAREL (bupivacaine liposome injectable suspension) 133mg/10mL 10 vials in one carton	01/01/2025	136.58	2412.90	02/02/2043	Single Source Drug	None	None	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000484	Pacira Pharmaceuticals, Inc.	04/24/2025	65250013304	EXPAREL (bupivacaine liposome injectable suspension) 133mg/10mL 4 vials in one carton	01/01/2025	54.63	965.15	02/02/2043	Single Source Drug	None	None	None	1	None	1	N/A	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000006	Pfizer	04/30/2025	51144005001	ADCETRIS, 50mg, single-dose vial, packaged singly	01/01/2025	458.00	12200.00	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	12/14/2023	Seagen	43000000000	None	On December 14, 2023 we acquired Seagen Inc., a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.	10878.00	10078.00	2011	4500.00	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409592101	Aminophylline Injection Rx, 250 mg/10 mL, VIAL (ML), 10	01/01/2025	41.31	454.41	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00008042303	Antivenin (micrurus fulvius equine origin), 10mL, VIAL (ML), 1	01/01/2025	381.13	8003.79	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009722402	ATGAM (lymphocyte immune globulin,antithymocyte (equine)), 50 mg/mL, Ampul(ML), 5	01/01/2025	3143.67	24101.48	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409963005	ATROPINE SULFATE (atropine sulfate), 0.05 mg/mL, SYRINGE (ML), 1	01/01/2025	24.65	271.19	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394063503	BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 1000 unit, VIAL (EA), 1	01/01/2025	47.60	1747.60	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394063603	BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 2000 unit, VIAL (EA), 1	01/01/2025	95.20	3495.20	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394063303	BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 250 unit, VIAL (EA), 1	01/01/2025	11.90	436.90	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394063703	BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 3000 unit, VIAL (EA), 1	01/01/2025	142.80	5242.80	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394063403	BeneFIX® (coagulation factor IX (recombinant)) Lyophilized Powder for Reconstitution Rx, 500 unit, VIAL (EA), 1	01/01/2025	23.80	873.80	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	60793070110	BICILLIN L-A (penicillin G benzathine), 1.2 million unit/2 mL, SYRINGE (ML), 1	01/01/2025	304.99	3354.87	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	60793070210	BICILLIN L-A (penicillin G benzathine), 2.4 million unit/4 mL, SYRINGE (ML), 1	01/01/2025	624.97	6874.69	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	60793070010	BICILLIN L-A (penicillin G benzathine), 600,000 unit/mL, SYRINGE (ML), 1	01/01/2025	176.10	1937.05	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069013501	BOSULIF (bosutinib), 100 mg, TABLET, 1	01/01/2025	601.92	20669.00	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069019301	BOSULIF (bosutinib), 400 mg, TABLET, 1	01/01/2025	601.92	20669.00	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069013601	BOSULIF (bosutinib), 500 mg, TABLET, 1	01/01/2025	601.92	20669.00	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	70255002503	BRAFTOVI (encorafenib), 75 mg, CAPSULE, 120	01/01/2025	477.11	16385.00	08/27/2030	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	70255002501	BRAFTOVI (encorafenib), 75 mg, CAPSULE, 180	01/01/2025	477.11	16385.00	08/27/2030	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409162301	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 1 mg/mL (1 mg/mL) Single Dose Glass Fliptop Vial, 10	01/01/2025	7.42	81.60	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409162601	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (2 mg/mL) Single Dose Glass Fliptop Vial, 10	01/01/2025	9.07	99.81	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409162602	Butorphanol Tartrate Injection - Controlled Substance - SCHEDULE IV Rx, 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial, 10	01/01/2025	12.78	140.53	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069033530	Cibinqo (abrocitinib) Tablet Rx, 100 mg, Tablet, 30	01/01/2025	278.37	5845.69	02/19/2034	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069043530	Cibinqo (abrocitinib) Tablet Rx, 200 mg, Tablet, 30	01/01/2025	278.37	5845.69	02/19/2034	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069023530	Cibinqo (abrocitinib) Tablet Rx, 50 mg, Tablet, 30	01/01/2025	278.37	5845.69	02/19/2034	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409330024	CIPROFLOXACIN, 400 MG/200 ML , INTRAVENOUS SOLUTION (ML), 24	01/01/2025	8.68	95.45	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009379422	CORVERT (ibutilide fumarate), 0.1 mg/mL, VIAL (ML), 10	01/01/2025	10.98	559.83	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009379401	CORVERT (ibutilide fumarate), 1 mg/10 mL, VIAL (ML), 10	01/01/2025	10.98	559.83	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409233725	Deferoxamine Mesylate Injection Rx, 2 g, Single Dose Glass Fliptop Vial, 4	01/01/2025	14.10	155.14	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409118130	Demerol (meperidine hydrochloride) Injection - Controlled Substance - SCHEDULE II Rx, 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial, 1	01/01/2025	12.49	137.41	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009027101	DEPO-ESTRADIOL (estradiol cypionate), 5 mg/mL, VIAL (ML), 1	01/01/2025	20.30	223.33	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409741903	Dextran (dextran) Injection Rx, 500 mL (10% LMD in 0.9% Sodium Chloride), Intravenous solution, 12	01/01/2025	48.22	530.44	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409741803	Dextran (dextran) Injection Rx, 500 mL (10% LMD in 5% Dextrose), Intravenous solution, 12	01/01/2025	46.85	515.31	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409321312	Diazepam Injection - Controlled Substance - SCHEDULE IV Rx, 5 mg/mL, VIAL (ML), 10	01/01/2025	50.11	551.17	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409234632	Dobutamine Hydrochloride, 1mg/ml, Vial, 12	01/01/2025	24.17	145.03	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409234732	Dobutamine Hydrochloride, 2mg/ml, Vial, 12	01/01/2025	66.43	250.96	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409372432	Dobutamine Hydrochloride, 4mg/ml, Vial, 12	01/01/2025	14.59	257.78	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409781022	Dopamine Hydrochloride in 5% Dextrose Injection Rx, 1,600 mcg/mL (400 mg/250 mL), Flexible Container, 12	01/01/2025	24.71	271.81	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409780922	Dopamine Hydrochloride in 5% Dextrose Injection Rx, 1,600 mcg/mL (800 mg/500 mL), Flexible Container, 12	01/01/2025	24.84	190.47	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409780924	Dopamine Hydrochloride in 5% Dextrose Injection Rx, 3,200 mcg/mL (800 mg/250 mL), Flexible Container, 12	01/01/2025	22.87	251.55	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409493301	Epinephrine Injection Rx, 1mg/10mL (0.1 mg/mL) ABBOJECT Single-dose syringe, 10	01/01/2025	9.28	102.08	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409648201	Erythrocin (lactobionate) IV Rx, 500 mg, Single Dose Glass Fliptop Vial, 10	01/01/2025	45.44	954.28	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	55724021121	Eucrisa® (crisaborole) ointment, 2% for topical use Rx, 20 mg/gm (100 gm), Tube, 1	01/01/2025	30.52	793.41	12/29/2029	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	55724021111	Eucrisa® (crisaborole) ointment, 2% for topical use Rx, 20 mg/gm (60 gm), Tube, 1	01/01/2025	42.91	1115.68	12/29/2029	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409909422	FENTANYL CITRATE (fentanyl citrate), 50 mcg/mL, VIAL (ML), 2	01/01/2025	9.24	47.74	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069021702	Fragmin® (dalteparin sodium) Injection Rx, 10,000 IU/1 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	60.38	1268.05	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069022002	Fragmin® (dalteparin sodium) Injection Rx, 12,500 IU/0.5 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	75.49	1585.19	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069022302	Fragmin® (dalteparin sodium) Injection Rx, 15,000 IU/0.6 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	90.58	1902.10	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069022802	Fragmin® (dalteparin sodium) Injection Rx, 18,000 IU/0.72 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards test potency, 10	01/01/2025	108.69	2282.52	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069019502	Fragmin® (dalteparin sodium) Injection Rx, 2,500 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	18.61	390.80	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069019602	Fragmin® (dalteparin sodium) Injection Rx, 5,000 IU/0.2 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	30.19	634.02	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069020602	Fragmin® (dalteparin sodium) Injection Rx, 7,500 IU/0.3 mL Single-dose Prefilled Syringe Pre-assembled w/Needle Guards, 10	01/01/2025	45.29	951.14	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069023201	Fragmin® (dalteparin sodium) Injection Rx, 95,000 IU/3.8 mL Multidose Vial, 1	01/01/2025	51.90	1089.95	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409120703	Gentamicin Sulfate Injection Rx, 40 mg/mL (80 mg/2 mL) Single Dose Glass Fliptop Vial, 25	01/01/2025	2.58	88.53	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409001230	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 12500 unit/250 mL, INTRAVENOUS SOLUTION, 250	01/01/2025	36.92	406.07	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409765030	Heparin Sodium (0.45% Sodium Chloride) Injection Rx, 25000 unit/250 mL (100 unit/mL), INTRAVENOUS SOLUTION, 250	01/01/2025	21.34	448.11	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409724803	HEXTEND (hetastarch/electrolyte solution,lactated), 500mL, Vial, 12	01/01/2025	65.82	340.07	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409155554	HEXTEND LACTATED ELECTROLYTE (hetastarch/electrolyte solution,lactated), 500mL, Vial, 12	01/01/2025	115.04	1265.40	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409128337	HYDROMORPHONE HCL (hydromorphone HCl), 1 mg/mL, SYRINGE (ML), 10	01/01/2025	4.90	53.93	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409263401	HYDROMORPHONE HCL (hydromorphone HCl), 10 mg/mL, VIAL (ML), 1	01/01/2025	38.15	81.01	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409131236	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, SYRINGE (ML), 10	01/01/2025	6.57	72.27	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409336510	HYDROMORPHONE HCL (hydromorphone HCl), 2 mg/mL, VIAL (ML), 1	01/01/2025	1.81	20.97	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069018821	IBRANCE (palbociclib), 100 mg, CAPSULE, 1	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069048603	IBRANCE (palbociclib), 100 mg, TABLET, 21	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069018921	IBRANCE (palbociclib), 125 mg, CAPSULE, 1	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069068803	IBRANCE (palbociclib), 125 mg, TABLET, 21	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069018721	IBRANCE (palbociclib), 75 mg, CAPSULE, 1	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069028403	IBRANCE (palbociclib), 75 mg, TABLET, 21	01/01/2025	479.61	16462.00	03/05/2027	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069014501	INLYTA (axitinib), 1 mg, TABLET, 1	01/01/2025	616.33	21162.00	10/29/2025	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069015111	INLYTA (axitinib), 5 mg, TABLET, 1	01/01/2025	616.33	21162.00	10/29/2025	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409175410	MAGNESIUM SULFATE (magnesium sulfate), 4 mEq/mL (50 %), SYRINGE (ML), 1	01/01/2025	33.68	370.46	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	70255001002	MEKTOVI (binimetinib), 15 mg, TABLET, 180	01/01/2025	468.23	16075.97	03/13/2026	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409189323	MORPHINE SULFATE (morphine sulfate), 10 mg/mL, SYRINGE (ML), 10	01/01/2025	5.08	55.86	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409189023	MORPHINE SULFATE (morphine sulfate), 2 mg/mL, SYRINGE (ML), 10	01/01/2025	4.29	47.15	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409189123	MORPHINE SULFATE (morphine sulfate), 4 mg/mL, SYRINGE (ML), 10	01/01/2025	4.32	47.52	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	61703032518	Pamidronate Disodium, 6MG/ML, Vial, 10	01/01/2025	4.13	45.39	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00046257512	Premphase® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.625 mg/5 mg, Tablet, 28	01/01/2025	5.80	247.61	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00046110511	Prempro® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.3 mg-1.5 mg, TABLET, 28	01/01/2025	5.80	247.61	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00046110611	Prempro® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.45 mg/1.5 mg, Tablet, 28	01/01/2025	5.80	247.61	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00046110711	Prempro® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.625 mg/2.5 mg Tablet, 28	01/01/2025	5.80	247.61	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00046110811	Prempro® (conjugated estrogens/medroxy progesterone acetate) Tablets Rx, 0.625 mg/5 mg, Tablet, 28	01/01/2025	5.80	247.61	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409190201	Procainamide Hydrochloride Injection Rx, 100 mg/mL (1,000 mg/10 mL) Multiple Dose Glass Fliptop Vial, 25	01/01/2025	1035.73	3337.35	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009316906	PROSTIN VR (alprostadil), 500 mcg/1ML,Ampoule, 5	01/01/2025	38.40	806.40	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009021505	PROSTIN VR (alprostadil), 500 mcg/ML, Ampul, 5	01/01/2025	38.40	806.40	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409553414	Sodium Bicarbonate Injection Rx, 4.2% (5mEq/10mL) per glass Abboject® syringe, 10	01/01/2025	20.11	221.21	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409491614	Sodium Bicarbonate Injection Rx, 7.5% (44/6 mEq/50mL) per glass Abboject® syringe, 10	01/01/2025	26.05	286.52	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409490014	Sodium Bicarbonate Injection Rx, 8.4% (10mEq/10mL) per glass vial Abboject® syringe, 10	01/01/2025	25.97	285.68	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409663714	Sodium Bicarbonate Injection Rx, 8.4% (50mEq/50mL) per glass Abbotject® syringe, 10	01/01/2025	19.18	210.99	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009001612	SOLU-CORTEF (hydrocortisone sodium succinate) 500 mg/4 mL, VIAL (EA), 1	01/01/2025	3.97	83.28	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009082501	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg, VIAL (EA), 1	01/01/2025	2.38	18.24	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009001103	SOLU-CORTEF (hydrocortisone sodium succinate), 100 mg/2 mL, VIAL EA, 1	01/01/2025	1.50	22.92	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009001305	SOLU-CORTEF (hydrocortisone sodium succinate), 250 mg/2 mL VIAL (EA), 1	01/01/2025	2.77	42.41	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009001104	SOLU-CORTEF hydrocortisone sodium succinate), 100 mg/2 mL, VIAL (EA), 1	01/01/2025	26.79	562.50	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009001306	SOLU-CORTEF hydrocortisone sodium succinate), 250 mg/2 mL, VIAL (EA) 1	01/01/2025	49.54	1040.43	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009000501	SOLU-CORTEF(hydrocortisone sodium succinate), 1000 mg/8 mL, VIAL EA 1	01/01/2025	7.93	166.50	None	Innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009716601	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 10 mg, VIAL (EA), 1	01/01/2025	24.11	291.95	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009716630	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 10 mg/1 mL Syringe, 30	01/01/2025	723.16	8758.27	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009716801	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 15 mg, VIAL (EA), 1	01/01/2025	36.16	437.95	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009716830	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 15 mg/1 mL Syringe, 30	01/01/2025	1084.83	13138.55	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009718801	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 20 mg, VIAL (EA), 1	01/01/2025	48.21	583.89	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009718830	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 20 mg/ 1 mL Syringe, 30	01/01/2025	1446.35	17516.93	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009719901	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 25 mg, VIAL (EA), 1	01/01/2025	60.26	729.86	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009719930	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 25mg/1 mL Syringe, 30	01/01/2025	1807.93	21896.06	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009720001	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 30 mg, VIAL (EA), 1	01/01/2025	72.32	875.84	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00009720030	Somavert® (pegvisomant) Injection with Prefilled Diluent Syringe Rx, 30 mg/1 mL Syringe, 30	01/01/2025	2169.51	26275.20	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409338221	SUFENTANIL CITRATE (sufentanil citrate), 50 mcg/mL, VIAL (ML), 1	01/01/2025	8.58	94.36	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069029630	Talzenna® (talazoparib) Rx, 0.25MG CAP, 30	01/01/2025	300.83	6314.00	10/19/2029	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069150130	Talzenna® (talazoparib) Rx, 0.5MG CAP, 30	01/01/2025	901.51	18941.00	10/19/2029	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069175130	Talzenna® (talazoparib) Rx, 0.75MG CAPSULE, 30	01/01/2025	901.51	18941.00	10/19/2029	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069119530	Talzenna® (talazoparib) Rx, 1MG CAP, 30	01/01/2025	901.51	18941.00	10/19/2029	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409159304	THAM (tromethamine), 36 mg/mL (0.3 M), INTRAVENOUS SOLUTION, 6	01/01/2025	214.14	2355.50	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00005010010	Trumenba® (meningococcal group B vaccine) Injection Rx, 0.5 mL Pre-filled Syringe, 10	02/01/2025	170.56	2065.68	10/29/2026	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00005010005	Trumenba® (meningococcal group B vaccine) Injection Rx, 0.5 mL Pre-filled Syringe, 5	02/01/2025	85.28	1032.84	10/29/2026	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00409963305	Verapamil Hydrochloride Injection Rx, 2.5 mg/mL (10 mg/4 mL) Ansyr Plastic Syringe, 10	01/01/2025	89.38	983.19	None	Non-innovator Multiple Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069814120	XALKORI (crizotinib), 200 mg, CAPSULE, 1	01/01/2025	1345.65	23773.10	10/08/2029	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069814020	XALKORI (crizotinib), 250 mg, CAPSULE, 1	01/01/2025	1345.65	23773.10	10/08/2029	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069100201	XELJANZ (tofacitinib citrate), 10 mg, TABLET, 1	01/01/2025	289.20	6073.14	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069100101	XELJANZ (tofacitinib citrate), 5 mg, TABLET, 1	01/01/2025	289.20	6073.14	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069050130	XELJANZ XR (tofacitinib citrate), 11 mg, TABLET, EXTENDED RELEASE 24 HR, 1	01/01/2025	289.20	6073.14	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069050230	XELJANZ XR (tofacitinib citrate), 22 mg, TABLET, EXTENDED RELEASE 24 HR, 30	01/01/2025	289.20	6073.14	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	00069102902	Xeljanz® (tofacitinib ) Oral Solution Rx, 1 mg/mL, SOLUTION ORAL, 240	01/01/2025	231.36	4858.51	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394002403	Xyntha Solofuse® (antihemophilic factor (recombinant), plasma/albumin-free) For Intravenous Use, Freeze-Dried Powder in Prefilled Dual-Chamber Syringe Rx, 1,000 IU (nominal) Single Use Prefilled Dual-chamber Syringe, 1	01/01/2025	91.00	1911.00	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394002503	Xyntha Solofuse® (antihemophilic factor (recombinant), plasma/albumin-free) For Intravenous Use, Freeze-Dried Powder in Prefilled Dual-Chamber Syringe Rx, 2,000 IU (nominal) Single Use Prefilled Dual-chamber Syringe, 1	01/01/2025	182.00	3822.00	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394002203	Xyntha Solofuse® (antihemophilic factor (recombinant), plasma/albumin-free) For Intravenous Use, Freeze-Dried Powder in Prefilled Dual-Chamber Syringe Rx, 250 IU (nonimal) Single Use Prefilled Dual-chamber Syringe, 1	01/01/2025	22.75	477.75	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394001603	Xyntha Solofuse® (antihemophilic factor (recombinant), plasma/albumin-free) For Intravenous Use, Freeze-Dried Powder in Prefilled Dual-Chamber Syringe Rx, 3,000 IU (nominal) Single Use Prefilled Dual-chamber Syringe, 1	01/01/2025	273.00	5733.00	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394002303	Xyntha Solofuse® (antihemophilic factor (recombinant), plasma/albumin-free) For Intravenous Use, Freeze-Dried Powder in Prefilled Dual-Chamber Syringe Rx, 500 IU (nominal) Single Use Prefilled Dual-chamber Syringe, 1	01/01/2025	45.50	955.50	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394001401	Xyntha® (antihemophilic factor (recombinant), plasma/albumin-free ) For Intravenous Use, Freeze-Dried Powder Rx, 1,000 IU per Vial (nominal) Single Use Vial, 1	01/01/2025	91.00	1911.00	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394001501	Xyntha® (antihemophilic factor (recombinant), plasma/albumin-free ) For Intravenous Use, Freeze-Dried Powder Rx, 2,000 IU per Vial (nominal) Single Use Vial, 1	01/01/2025	182.00	3822.00	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394001201	Xyntha® (antihemophilic factor (recombinant), plasma/albumin-free ) For Intravenous Use, Freeze-Dried Powder Rx, 250 IU per Vial (nominal) Single Use Vial, 1	01/01/2025	22.75	477.75	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000006	Pfizer	04/30/2025	58394001301	Xyntha® (antihemophilic factor (recombinant), plasma/albumin-free ) For Intravenous Use, Freeze-Dried Powder Rx, 500 IU per Vial (nominal) Single Use Vial, 1	01/01/2025	45.50	955.50	None	Single Source Drug	None	None	None	1	A medicines price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.	None	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. (2) For Columns 14-22, Pfizer has not provided a response for products that were not acquired from an unrelated company in the previous 5 years. (3) While Pfizer does not believe any change improvments for a specific drug products price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizers general drug pricing philosophy and policy is available on Pfizers website.
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121064610	AMANTADINE HYDROCHLORIDE (AMANTADINE HYDROCHLORIDE) 50mg/5mL Oral Solution, 10mL Cup [Qty: 100]	01/02/2025	35.58	394.93	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121202410	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 10mL Cup [Qty: 1]	01/02/2025	4.85	53.88	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121202495	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 10mL Cup [Qty: 10]	01/02/2025	48.53	538.78	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121303615	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 15mL Cup [Qty: 1]	01/02/2025	7.28	80.82	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121303695	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 15mL Cup [Qty: 10]	01/02/2025	72.80	808.18	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121404874	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 20mL Cup [Qty: 1]	01/02/2025	9.71	107.76	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121404895	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 20mL Cup [Qty: 10]	01/02/2025	97.07	1077.57	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121101205	LACOSAMIDE (LACOSAMIDE) 10mg/mL Oral Solution, 5mL Cup [Qty: 1]	01/02/2025	2.43	26.94	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121101295	LACOSAMIDE(LACOSAMIDE) 10mg/mL Oral Solution, 5mL Cup [Qty: 10]	01/02/2025	24.27	269.40	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121115440	LACTULOSE (LACTULOSE) - 10g/15mL Oral Solution, 30mL Cup [Qty: 40]	01/02/2025	13.10	78.62	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121457715	LACTULOSE (LACTULOSE) 10g/15mL Oral Solution, 15mL Cup [Qty: 1]	01/02/2025	0.29	1.75	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121457740	LACTULOSE (LACTULOSE) 10g/15mL Oral Solution, 15mL Cup [Qty: 40]	01/02/2025	11.66	69.98	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121115430	LACTULOSE (LACTULOSE) 10g/15mL Oral Solution, 30mL Cup [Qty: 1]	01/02/2025	0.33	1.97	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121115400	LACTULOSE (LACTULOSE) 10g/15mL Oral Solution, 30mL Cup [Qty: 100]	01/02/2025	30.25	181.50	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	03/03/2025	00121077001	LORAZEPAM 2mg/mL Oral Concentrate, 30mL bottle [Qty: 1]	03/03/2025	16.53	31.55	None	Non-innovator Multiple Source Drug	None	None	None	1	The generic Lorazepam oral liquid market currently has 3 suppliers in the US. This market has recently experienced a supply disruption which is putting significant strain on PAI Pharma. PAI Pharmas supply position is constrained and cant take on the additional customer request without investments (API, components, resources, etc.) and managing long lead time materials. PAI Pharma is raising WAC to improve supply position and offset the add complexity.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121135010	VALPROIC ACID (VALPROIC ACID) 250mg/5mL Oral Solution, 10mL Cup [Qty: 1]	01/02/2025	0.23	2.47	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121135000	VALPROIC ACID (VALPROIC ACID) 250mg/5mL Oral Solution, 10mL Cup [Qty: 100]	01/02/2025	22.22	246.70	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121467505	VALPROIC ACID (VALPROIC ACID) 250mg/5mL Oral Solution, 5mL Cup [Qty: 1]	01/02/2025	0.12	1.37	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121467500	VALPROIC ACID (VALPROIC ACID) 250mg/5mL Oral Solution, 5mL Cup [Qty: 100]	01/02/2025	12.35	137.14	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000135	Pharmaceutical Associates, Inc	01/06/2025	00121467540	VALPROIC ACID (VALPROIC ACID) 250mg/5mL Oral Solution, 5mL Cup [Qty: 40]	01/02/2025	7.79	86.44	None	Non-innovator Multiple Source Drug	None	None	None	1	PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.	None	No change or improvement	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000410	PharmaEssentia USA Corporation	04/14/2025	73536050001	Besremi Subcutaneous Solution Prefilled Syringe 500 MCG/ML	01/17/2025	505.00	8923.00	02/26/2034	Single Source Drug	None	None	None	1	PharmaEssentia USA Corporation prices BESREMi using a variety of inforamtion and factors that are not public in nature and are related to confidential costs incurred coupled with expected drug utilization in a limited therapeutic class. Some factors that led to this increase in price include incremental costs of doing business, higher inflation of cost of goods, and increased participation and levels of discounting arrangements to government programs.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000469	Pharming Healthcare Inc	02/19/2025	71274035002	Ruconest 2100 U; Injection; Powder for Solution; 1 Carton	01/01/2025	450.00	8075.00	10/07/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000469	Pharming Healthcare Inc	02/19/2025	71274035001	Ruconest C1 Esterase Inhibitor (Recombinant) 2100 UNIT Solution Reconstituted 1 EA UD	01/01/2025	450.00	8075.00	10/07/2026	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000118	Progenics Pharmaceuticals, Inc.	04/14/2025	71258002201	Pylarify PIFLUFOLASTAT F-18 50 mL in 1 VIAL, MULTI-DOSE INJECTION	02/01/2025	312.84	5535.52	06/09/2037	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain
Rx0000536	Protega Pharmaceuticals, Inc.	04/03/2025	81140010210	RoxyBond Oral Tablet Abuse-Deterrent 15 MG 100 tablets per bottle	02/05/2025	170.99	1898.16	08/12/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000536	Protega Pharmaceuticals, Inc.	04/03/2025	81140010310	RoxyBond Oral Tablet Abuse-Deterrent 30 MG 100 tablets per bottle	02/05/2025	230.44	2558.14	08/12/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000536	Protega Pharmaceuticals, Inc.	04/03/2025	81140010110	RoxyBond Oral Tablet Abuse-Deterrent 5 MG 100 tablets per bottle	02/05/2025	138.65	1539.13	08/12/2028	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000220	Puma Biotechnology, Inc.	03/02/2025	70437024033	Nerlynx Oral Tablet 40 mg, 133 tablet package	02/03/2025	1145.00	17510.00	07/18/2031	Single Source Drug	None	None	12130000	None	Inflation has driven up costs in almost all areas of operations.	None	There was no change or improvement that necessitated the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000220	Puma Biotechnology, Inc.	03/02/2025	70437024018	Nerlynx Oral Tablet 40 mg, 180 tablet package	02/03/2025	1550.00	23700.00	07/18/2031	Single Source Drug	None	None	230470000	None	Inflation has driven up costs in almost all areas of operations.	None	There was no change or improvement that necessitated the price increase.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000056	Purdue Pharma LP	03/03/2025	59011027660	HYSINGLA ER 100MG TABLETS 60S	01/01/2025	211.17	3589.87	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011027160	HYSINGLA ER 20MG TABLETS 60S	01/01/2025	45.21	768.51	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011027260	HYSINGLA ER 30MG TABLETS 60S	01/01/2025	65.99	1121.77	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011027360	HYSINGLA ER 40MG TABLETS 60S	01/01/2025	88.90	1511.28	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011027460	HYSINGLA ER 60MG TABLETS 60S	01/01/2025	123.10	2092.64	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011027560	HYSINGLA ER 80MG TABLETS 60S	01/01/2025	165.96	2821.37	12/21/2031	Single Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011041010	OXYCONTIN 10MG TABLETS 100S	01/01/2025	33.33	566.56	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011041020	OXYCONTIN 10MG TABLETS HUD 20S	01/01/2025	6.84	116.33	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011041510	OXYCONTIN 15MG TABLETS 100S	01/01/2025	49.06	834.05	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011041520	OXYCONTIN 15MG TABLETS HUD 20S	01/01/2025	10.07	171.13	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011042010	OXYCONTIN 20MG TABLETS 100S	01/01/2025	62.15	1056.59	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011042020	OXYCONTIN 20MG TABLETS HUD 20S	01/01/2025	12.75	216.73	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011043010	OXYCONTIN 30MG TABLETS 100S	01/01/2025	86.44	1469.44	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011043020	OXYCONTIN 30MG TABLETS HUD 20S	01/01/2025	17.74	301.50	03/29/2030	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011044010	OXYCONTIN 40MG TABLETS 100S	01/01/2025	106.44	1809.51	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011044020	OXYCONTIN 40MG TABLETS HUD 20S	01/01/2025	21.83	371.04	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011046010	OXYCONTIN 60MG TABLETS 100S	01/01/2025	150.71	2561.99	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011046020	OXYCONTIN 60MG TABLETS HUD 20S	01/01/2025	30.92	525.61	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011048010	OXYCONTIN 80MG TABLETS 100S	01/01/2025	185.74	3157.54	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000056	Purdue Pharma LP	03/03/2025	59011048020	OXYCONTIN 80MG TABLETS HUD 20S	01/01/2025	38.10	647.72	08/24/2027	Innovator Multiple Source Drug	None	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None	None	As all companies do, from time to time we review and update our pricing based on various business and marketplace factors. We remain committed to serving patients who rely on our FDA-approved medicines.
Rx0000342	PureTek Corporation	04/02/2025	59088000381	Bruselix, Vitamin C, Zinc, Arnica Montana Extract, Bromelain, Diosmin, Rutin, Citrus Bioflavonoids, Hesperidin Methyl Chalcone, tablets (14ct)	04/01/2025	776.00	1604.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088016254	Diatrol Multivitamin (30ct), caplets, Vita A 900mcg, Vit C 50mg, Vit D3 18.75 mcg, Vit E 13.5mg, Vit K1 90 mcg, Thiamin 4mg, Vit B2 4mg, Niacin 24mg, Vit B6 8mg, Folate 1700mcg, Vit B12 8,cg, Biotin 30mcg, Panthothenic Acid 8mg, Chromium 200mcg	04/01/2025	818.42	1646.42	None	Single Source Drug	None	None	None	1	Raw material, component and manufacturing costs. New or stricter regulatory requirements increase testing, validation, and documentation costs as well as stability studies, batch testing, and third-party certifications. Rising fuel prices, import/export duties, or increased warehousing expenses. Rising costs of goods and services in general.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088000854	Finazol, Vit A, Vit C, Vit D3, Vitamin E, Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Biotin, Pantothenic Acid, Calcium, Iron, Iodine, Magnesium, Zinc, Selenium, Copper, Manganese, Chromium, Molybdenum, Potassium, Boron, caplets, 30ct	04/01/2025	776.00	1604.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088001554	Flotrex 0.5mg, Vitamin A, Vitamin C, Vitamin D3, Vitamin E, Thiamin, Vitamin E, Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Fluoride, chewable tablets (30ct)	04/01/2025	776.00	1604.00	None	Single Source Drug	None	None	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088020407	Lidotral 5% Gel, Lidocaine HCI 5%, (3oz)	04/01/2025	818.42	1646.42	None	Single Source Drug	None	None	None	1	Raw material, component and manufacturing costs. New or stricter regulatory requirements increase testing, validation, and documentation costs as well as stability studies, batch testing, and third-party certifications. Rising fuel prices, import/export duties, or increased warehousing expenses. Rising costs of goods and services in general.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088035003	Lidotral 5% Spray, Lidocaine HCI 5%, (1fl oz)	04/01/2025	818.42	1646.42	None	Single Source Drug	None	None	None	1	Raw material, component and manufacturing costs. New or stricter regulatory requirements increase testing, validation, and documentation costs as well as stability studies, batch testing, and third-party certifications. Rising fuel prices, import/export duties, or increased warehousing expenses. Rising costs of goods and services in general.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088022700	Salycim Cream, Salicylic Acid 6%, (2oz)	04/01/2025	818.42	1646.42	None	Single Source Drug	None	None	None	1	Raw material, component and manufacturing costs. New or stricter regulatory requirements increase testing, validation, and documentation costs as well as stability studies, batch testing, and third-party certifications. Rising fuel prices, import/export duties, or increased warehousing expenses. Rising costs of goods and services in general.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000342	PureTek Corporation	04/02/2025	59088032607	Scartrate Cream, Dimethicone 5% + Allantoin 2.25%, (3oz)	04/01/2025	818.42	1646.42	None	Single Source Drug	None	None	None	1	Raw material, component and manufacturing costs. New or stricter regulatory requirements increase testing, validation, and documentation costs as well as stability studies, batch testing, and third-party certifications. Rising fuel prices, import/export duties, or increased warehousing expenses. Rising costs of goods and services in general.	None	None	1	None	None	None	None	None	None	None	None	None	None	None